NPI: 1346230323 · LAS VEGAS, NV 89118 · General Acute Care Hospital · NPI assigned 10/21/2005
Authorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
| Authorized Official | FILTON, STEVE (CFO, SENIOR VP) |
| NPI Enumeration Date | 10/21/2005 |
Other providers sharing the same authorized official: FILTON, STEVE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 105,534 | $1.65M |
| 2019 | 285,093 | $5.70M |
| 2020 | 253,249 | $5.05M |
| 2021 | 242,174 | $5.23M |
| 2022 | 234,015 | $5.41M |
| 2023 | 249,937 | $5.62M |
| 2024 | 203,724 | $4.92M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 61,953 | 51,095 | $7.10M |
| G0378 | Hospital observation service, per hour | 28,361 | 20,368 | $3.29M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 31,888 | 28,360 | $2.89M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9,418 | 7,904 | $2.16M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 31,541 | 26,005 | $1.65M |
| 70450 | Computed tomography, head or brain; without contrast material | 15,195 | 13,003 | $1.31M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6,278 | 5,412 | $1.05M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 4,044 | 3,360 | $982K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 43,993 | 34,598 | $782K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 30,172 | 23,837 | $758K |
| 96361 | Intravenous infusion, hydration; each additional hour | 34,473 | 25,788 | $754K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1,397 | 1,205 | $622K |
| 96375 | Therapeutic injection; each additional sequential IV push | 34,995 | 25,560 | $619K |
| 72125 | Computed tomography, cervical spine; without contrast material | 3,665 | 3,274 | $492K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 10,252 | 9,005 | $358K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 22,500 | 15,114 | $320K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 93,102 | 64,595 | $287K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 50,165 | 38,908 | $258K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7,268 | 6,591 | $255K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 8,599 | 6,938 | $253K |
| 80053 | Comprehensive metabolic panel | 52,769 | 41,102 | $251K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1,998 | 1,637 | $249K |
| 0450 | Emergency room services | 4,985 | 4,385 | $244K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 16,626 | 13,553 | $224K |
| 84484 | 48,544 | 25,457 | $222K | |
| 71045 | Radiologic examination, chest; single view | 31,930 | 26,198 | $211K |
| 96376 | 15,710 | 8,738 | $205K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4,056 | 3,622 | $189K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 2,816 | 2,424 | $170K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2,538 | 2,383 | $166K |
| 59025 | Fetal non-stress test | 4,560 | 3,415 | $163K |
| 72131 | 1,285 | 1,129 | $159K | |
| 36415 | Collection of venous blood by venipuncture | 108,607 | 69,011 | $154K |
| 71046 | Radiologic examination, chest; 2 views | 12,570 | 10,929 | $153K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 2,955 | 2,551 | $147K |
| 76830 | Ultrasound, transvaginal | 2,041 | 1,774 | $146K |
| 84702 | 23,316 | 19,572 | $144K | |
| J2785 | Injection, regadenoson, 0.1 mg | 1,319 | 1,134 | $140K |
| 76801 | 2,425 | 2,012 | $139K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 38,240 | 28,673 | $135K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 9,837 | 3,481 | $127K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2,678 | 1,343 | $121K |
| 70486 | 932 | 836 | $110K | |
| 83880 | 9,639 | 7,775 | $105K | |
| 70496 | 350 | 304 | $104K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 1,635 | 1,366 | $96K |
| 93971 | 2,110 | 1,806 | $95K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 1,325 | 1,142 | $92K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 3,290 | 2,056 | $87K |
| 93970 | 1,022 | 882 | $80K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2,195 | 1,603 | $78K |
| 83690 | 24,462 | 19,886 | $78K | |
| 70498 | 318 | 276 | $77K | |
| 97162 | 3,269 | 2,507 | $76K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 453 | 362 | $75K |
| 83605 | 17,488 | 12,380 | $72K | |
| 90715 | 1,930 | 1,730 | $72K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2,077 | 1,653 | $70K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3,491 | 3,092 | $65K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 789 | 696 | $63K |
| 97166 | 2,738 | 2,138 | $61K | |
| 97535 | Self-care/home management training, each 15 minutes | 6,030 | 3,194 | $59K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2,110 | 1,672 | $57K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 24,063 | 14,996 | $55K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2,196 | 2,028 | $48K |
| 81001 | 34,932 | 29,144 | $47K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 4,992 | 4,130 | $45K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3,465 | 3,281 | $45K |
| 85730 | 23,305 | 17,975 | $44K | |
| 73564 | 2,244 | 2,009 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 13,616 | 11,387 | $43K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 696 | 568 | $41K |
| 87040 | 8,724 | 4,723 | $40K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2,373 | 1,898 | $39K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 927 | 239 | $38K |
| 85610 | 28,500 | 21,816 | $36K | |
| 73630 | 2,194 | 1,988 | $34K | |
| 85379 | 7,873 | 6,748 | $34K | |
| 73610 | 1,897 | 1,717 | $32K | |
| 83735 | 13,516 | 9,769 | $31K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1,778 | 1,478 | $30K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1,778 | 1,478 | $30K |
| 81025 | 11,818 | 10,078 | $30K | |
| 97116 | 4,669 | 2,391 | $29K | |
| 73130 | 1,657 | 1,505 | $29K | |
| 84145 | 3,051 | 2,552 | $27K | |
| J3370 | Injection, vancomycin hcl, 500 mg | 2,712 | 1,443 | $26K |
| 87641 | 4,888 | 3,770 | $26K | |
| 73030 | 1,805 | 1,614 | $25K | |
| 93017 | 1,410 | 1,214 | $24K | |
| 74022 | 986 | 860 | $24K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1,013 | 205 | $24K |
| 97161 | 1,100 | 843 | $23K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 8,603 | 6,220 | $23K |
| 11043 | 181 | 99 | $21K | |
| 72100 | 1,461 | 1,298 | $21K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1,889 | 1,686 | $21K |
| 87186 | 5,992 | 4,226 | $20K | |
| 80076 | 5,824 | 4,846 | $20K | |
| 73110 | 973 | 875 | $20K | |
| 82550 | 7,416 | 5,870 | $19K | |
| 84443 | Thyroid stimulating hormone (TSH) | 3,338 | 2,826 | $18K |
| 0250 | 794 | 326 | $17K | |
| 70491 | 100 | 92 | $17K | |
| 80069 | 7,167 | 3,987 | $16K | |
| 96367 | 1,126 | 893 | $16K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 13,081 | 10,770 | $16K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 32,059 | 23,895 | $16K |
| 82962 | 22,776 | 7,466 | $16K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1,617 | 449 | $15K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 9,766 | 8,698 | $14K |
| 93880 | 288 | 212 | $14K | |
| Z7502 | 359 | 320 | $13K | |
| 80061 | Lipid panel | 3,316 | 2,750 | $13K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 2,422 | 1,816 | $13K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 2,646 | 1,446 | $12K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 3,239 | 2,192 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | 4,724 | 3,788 | $12K |
| 81003 | 11,743 | 9,839 | $11K | |
| 82803 | 1,749 | 1,141 | $11K | |
| 10060 | 148 | 133 | $11K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 308 | 293 | $10K |
| 86140 | 5,715 | 4,647 | $10K | |
| J1644 | Injection, heparin sodium, per 1000 units | 9,075 | 4,090 | $10K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 595 | 369 | $10K |
| 74018 | 927 | 756 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 6,803 | 4,166 | $9K |
| J0780 | Injection, prochlorperazine, up to 10 mg | 1,542 | 1,237 | $9K |
| 12001 | 256 | 235 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 10,257 | 8,474 | $9K |
| 87077 | 2,264 | 1,686 | $8K | |
| 85027 | 4,818 | 3,124 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 34 | 31 | $8K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 316 | 273 | $8K |
| 97165 | 497 | 372 | $7K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2,003 | 1,827 | $7K |
| 86901 | 7,557 | 6,202 | $7K | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 77 | 68 | $7K |
| J3490 | Unclassified drugs | 570 | 405 | $6K |
| 86850 | 5,775 | 4,689 | $6K | |
| 87070 | 2,269 | 1,845 | $6K | |
| 86900 | 7,153 | 5,866 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 74 | 72 | $6K |
| 82140 | 1,301 | 1,015 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | 8,341 | 6,177 | $5K |
| C1781 | Mesh (implantable) | 108 | 98 | $5K |
| 73502 | 318 | 278 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 6,942 | 5,008 | $5K |
| J1630 | Injection, haloperidol, up to 5 mg | 2,967 | 2,167 | $5K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 5,683 | 4,549 | $4K |
| 84439 | 1,357 | 1,135 | $4K | |
| 76775 | 184 | 161 | $4K | |
| 73080 | 251 | 230 | $4K | |
| 87205 | 2,711 | 2,103 | $4K | |
| J1953 | Injection, levetiracetam, 10 mg | 540 | 385 | $4K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 4,513 | 3,655 | $4K |
| 99199 | Unlisted special service, procedure or report | 79 | 71 | $4K |
| 12011 | 88 | 82 | $4K | |
| J2704 | Injection, propofol, 10 mg | 7,817 | 6,427 | $4K |
| J0456 | Injection, azithromycin, 500 mg | 1,346 | 908 | $3K |
| J2358 | Injection, olanzapine, long-acting, 1 mg | 356 | 250 | $3K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 139 | 106 | $3K |
| 73590 | 283 | 265 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 143 | 137 | $3K |
| 87210 | 1,543 | 1,295 | $3K | |
| 71101 | 149 | 134 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 5,028 | 3,683 | $3K |
| C9113 | Injection, pantoprazole sodium, per vial | 2,158 | 1,282 | $3K |
| 84132 | 2,299 | 1,734 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 1,533 | 1,224 | $3K |
| 72128 | 30 | 28 | $2K | |
| 82728 | 713 | 515 | $2K | |
| 99070 | 268 | 135 | $2K | |
| 84100 | 1,754 | 1,278 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 191 | 157 | $2K |
| 36430 | 131 | 88 | $2K | |
| 72040 | 167 | 139 | $2K | |
| 95819 | 16 | 12 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 785 | 659 | $2K |
| J3480 | Injection, potassium chloride, per 2 meq | 1,247 | 807 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 8,192 | 6,461 | $2K |
| J1790 | Injection, droperidol, up to 5 mg | 205 | 179 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | 948 | 460 | $2K |
| 87631 | 912 | 768 | $2K | |
| C1769 | Guide wire | 1,545 | 1,095 | $2K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 1,335 | 1,152 | $2K |
| 80074 | 111 | 97 | $2K | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 27 | 26 | $2K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 56 | 51 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 310 | 258 | $1K |
| 76870 | 62 | 54 | $1K | |
| 85652 | 1,527 | 1,233 | $1K | |
| 97163 | 83 | 63 | $1K | |
| 82010 | 415 | 365 | $1K | |
| 0270 | 269 | 120 | $1K | |
| 94664 | 282 | 157 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | 1,632 | 722 | $1K |
| Z7610 | 122 | 26 | $1K | |
| 73090 | 86 | 79 | $1K | |
| 29125 | 52 | 48 | $1K | |
| 84112 | 80 | 71 | $1K | |
| 76376 | 63 | 60 | $1K | |
| J2800 | Injection, methocarbamol, up to 10 ml | 420 | 347 | $1K |
| 87276 | 343 | 303 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 5,459 | 4,391 | $980.93 |
| 87275 | 342 | 302 | $976.86 | |
| J2359 | Injection, olanzapine, 0.5 mg | 123 | 86 | $942.80 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 61 | 26 | $853.73 |
| 86923 | 135 | 102 | $829.73 | |
| 87081 | 607 | 431 | $819.76 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 33 | 24 | $817.80 |
| 83615 | 454 | 344 | $762.95 | |
| 17250 | 18 | 12 | $732.48 | |
| 94644 | 35 | 29 | $719.51 | |
| 85018 | 1,289 | 921 | $718.92 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 166 | 90 | $706.26 |
| 82330 | 155 | 130 | $688.01 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 400 | 333 | $677.25 |
| 85014 | 1,221 | 867 | $670.36 | |
| G0008 | Administration of influenza virus vaccine | 82 | 61 | $668.40 |
| 99201 | 35 | 32 | $634.40 | |
| 72072 | 31 | 28 | $577.67 | |
| 97167 | 65 | 38 | $572.31 | |
| 96368 | 70 | 63 | $542.58 | |
| 86780 | 88 | 83 | $536.31 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 22 | 16 | $461.79 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 181 | 170 | $455.61 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 142 | 103 | $425.50 |
| 87486 | 36 | 25 | $406.98 | |
| 87581 | 36 | 25 | $406.98 | |
| 82805 | 44 | 28 | $404.81 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 285 | 264 | $404.47 |
| J3360 | Injection, diazepam, up to 5 mg | 26 | 22 | $295.36 |
| 82570 | 130 | 109 | $293.99 | |
| 87430 | 113 | 103 | $288.14 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 164 | 117 | $283.51 |
| 84550 | 136 | 109 | $268.98 | |
| 83550 | 169 | 141 | $268.14 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 66 | 50 | $267.92 |
| 87563 | 17 | 16 | $264.31 | |
| 87420 | 48 | 46 | $246.79 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 910 | 695 | $244.68 |
| 83540 | 159 | 137 | $194.81 | |
| 90686 | 54 | 45 | $193.81 | |
| A9270 | Non-covered item or service | 26,415 | 3,999 | $184.89 |
| 84295 | 179 | 139 | $177.56 | |
| J3411 | Injection, thiamine hcl, 100 mg | 37 | 24 | $138.97 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 12 | 12 | $132.42 |
| 97602 | 13 | 13 | $130.63 | |
| 36600 | 53 | 37 | $121.50 | |
| 64488 | 17 | 16 | $110.88 | |
| 84156 | 56 | 49 | $95.24 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 781 | 690 | $87.77 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 47 | 27 | $87.68 |
| J8540 | Dexamethasone, oral, 0.25 mg | 45 | 38 | $80.23 |
| J1836 | Injection, metronidazole, 10 mg | 80 | 54 | $52.96 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 17 | 14 | $44.51 |
| J1171 | Injection, hydromorphone, 0.1 mg | 185 | 126 | $40.41 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 42 | 39 | $31.19 |
| 82150 | 38 | 25 | $26.96 | |
| 85046 | 34 | 16 | $22.86 | |
| 82248 | 16 | 12 | $20.52 | |
| 84300 | 14 | 12 | $13.28 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 45 | 27 | $9.16 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 146 | 141 | $8.62 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 28 | 26 | $6.70 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 257 | 191 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 250 | 173 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 244 | 178 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 16 | 16 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 336 | 248 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 411 | 278 | $0.00 |
| 0353U | 535 | 504 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 27 | 13 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 175 | 138 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 365 | 243 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 36 | 25 | $0.00 |
| C1729 | Catheter, drainage | 17 | 13 | $0.00 |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 17 | 14 | $0.00 |